[1]
|
Ehrenforth, S., Kreuz, W., Scharrer, I., et al. (1992) Incidence of Development of Factor VIII and Factor IX Inhibitors in Hemophiliacs. The Lancet, 339, 594-598. https://doi.org/10.1016/0140-6736(92)90874-3
|
[2]
|
Tieu, P., Chan, A. and Matino, D. (2020) Molecular Mechanisms of Inhibitor Development in Hemophilia. Mediterranean Journal of Hematology and Infectious Diseases, 12, e2020001. https://doi.org/10.4084/mjhid.2020.001
|
[3]
|
Georgescu, MT., Lai, J.D., Hough, C. and Lillicrap, D. (2016) War and Peace: Factor VIII and the Adaptive Immune Response. Cellular Immunology, 301, 2-7. https://doi.org/10.1016/j.cellimm.2015.11.008
|
[4]
|
Hariti, G., Ferhat, Y., Cherif, N. and Messadi, W. (2023) The Correlation of Type F8 Gene Mutation on Inhibitor Development in a Single Centre Cohort of Severe Hemophilia a Patients. Haemophilia, 29, 29.
|
[5]
|
Sun, J., Li, Z., Huang, K., et al. (2022) F8 Gene Mutation Spectrum in Severe Hemophilia A with Inhibitors: A Large Cohort Data Analysis from a Single Center in China. Research and Practice in Thrombosis and Haemostasis, 6, e12723. https://doi.org/10.1002/rth2.12723
|
[6]
|
Shinozawa, K., Yada, K., Kojima, T., et al. (2021) Spectrum of F8 Genotype and Genetic Impact on Inhibitor Development in Patients with Hemophilia A from Multicenter Cohort Studies (J-HIS) in Japan. Thrombosis and Haemostasis, 121, 603-615. https://doi.org/10.1055/s-0040-1721385
|
[7]
|
Nasirnejad Sola, F., Morovvati, S., Sabetghadam Moghadam, M. and Entezari, M. (2020) Mutation Detection and Inhibitor Risk in Iranian Patients with Hemophilia A: Six Novel Mutations. Clinical Case Reports, 8, 2976-2985. https://doi.org/10.1002/ccr3.3294
|
[8]
|
龚鑫, 何志旭, 李燕, 等. 贵州省血友病A患儿治疗后抑制物形成的影响因素[J]. 贵州医科大学学报, 2023, 48(1): 77-81.
|
[9]
|
McGill, J.R., Simhadri, V.L. and Sauna, Z.E. (2021) HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHN Dataset. Frontiers in Medicine (Lausanne), 8, Article 663396. https://doi.org/10.3389/fmed.2021.663396
|
[10]
|
Mancuso, M.E., Fischer, K., Santagostino, E., et al. (2017) Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors. Thrombosis and Haemostasis, 117, 2274-2282. https://doi.org/10.1160/TH17-01-0059
|
[11]
|
Zhou, J., Ding, Q., Chen, Z., et al. (2015) Risk Factors Associated with Inhibitor Development in Chinese Patients with Haemophilia B. Haemophilia, 21, e286-e293. https://doi.org/10.1111/hae.12684
|
[12]
|
王稳, 崔东艳, 蒋丽娟, 等. 20例抑制物阳性的血友病A患者的临床分析[J]. 临床血液学杂志, 2021, 34(1): 31-34.
|
[13]
|
Ahmed, A.E. and Pratt, K.P. (2023) Race, Ethnicity, F8 Variants, and Inhibitor Risk: Analysis of the “My Life Our Future” Hemophilia A Database. Journal of Thrombosis and Haemostasis, 21, 800-813. https://doi.org/10.1016/j.jtha.2022.12.017
|
[14]
|
Tucunduva, A., Prezotti, A.N., Siqueira, L.H., et al. (2017) Lower Risk of Factor VIII Inhibitors among Severe Hemophilia A Patients with Indigenous Background from Brazil. Research and Practice in Thrombosis and Haemostasis, 1, 732-733.
|
[15]
|
Schwaab, R., Pavlova, A., Albert, T., Caspers, M. and Oldenburg, J. (2013) Significance of F8 Missense Mutations with Respect to Inhibitor Formation. Thrombosis and Haemostasis, 109, 464-470. https://doi.org/10.1160/TH12-07-0521
|
[16]
|
Gorski, M.M., Blighe, K., et al. (2016) Whole-Exome Sequencing to Identify Genetic Risk Variants Underlying Inhibitor Development in Severe Hemophilia A Patients. Blood, 127, 2924-2933. https://doi.org/10.1182/blood-2015-12-685735
|
[17]
|
Lotta, L.A., Fornili, M., Ambrogi, F., et al. (2013) Rare Genetic Variants of the Protein-Coding Area of the Genome and the Risk of Inhibitor Development: An Exome-Sequencing Study of 28 Patients with Severe Hemophilia A. Blood, 122, 571. https://doi.org/10.1182/blood.V122.21.571.571
|
[18]
|
Liu, G., Sun, J., Li, Z., Chen, Z., Wu, W. and Wu, R. (2023) F9 Mutations Causing Deletions Beyond the Serine Protease Domain Confer Higher Risk for Inhibitor Development in Hemophilia B. Blood, 141, 677-680. https://doi.org/10.1182/blood.2022017871
|
[19]
|
Álvaro-Benito, M. and Freund, C. (2020) Revisiting Nonclassical HLAII Functions in Antigen Presentation: Peptide Editing and Its Modulation. HLA, 96, 415⁃429. https://doi.org/10.1111/tan.14007
|
[20]
|
Kempton, C.L. and Payne, A.B. (2018) HLA-DRB1-Factor VIII Binding Is a Risk Factor for Inhibitor Development in Nonsevere Hemophilia: A Case-Control Study. Blood Advances, 2, 1750-1755. https://doi.org/10.1182/bloodadvances.2018019323
|
[21]
|
Diego, V.P., Luu, B.W., Garza, A., et al. (2020) Disentangling the Effects of HLA DRB1*15:01 and DQB1*06:02 to Establish the True HLA Risk Allele for Inhibitor Development in Treating Hemophilia A. Blood, 136, 1-2. https://doi.org/10.1182/blood-2020-142716
|
[22]
|
Ferrante, A., Mosher, B. and Hoffman, M. (2015) Immune-Related Gene Polymorphisms as Risk Factors for the Development of Factor VIII Inhibitors in Hemophilia A Patients: A Sibling-Pair Association Analysis (HUM1P.257). The Journal of Immunology, 194, 52.6. https://doi.org/10.4049/jimmunol.194.Supp.52.6
|
[23]
|
Pergantou, H., Moraloglou, V.O., Economou, M., et al. (2013) Impact of HLA Alleles and Cytokine Polymorphisms on Inhibitors Development in Children with Severe Haemophilia A. Haemophilia, 19, 706-710. https://doi.org/10.1111/hae.12168
|
[24]
|
Hosseinia, S., Arabib, S., Yaric, F., et al. (2019) HLA-DRB1*01:01, but Not HLA-DRB1:1503 or HLA-DRB1*11, Is Associated with Decreased Inhibitor Risk in Iranian Hemophilia A Patients. Transfusion and Apheresis Science, 58, 669-673. https://doi.org/10.1016/j.transci.2019.08.019
|
[25]
|
Naz, A., Ahmed, S., Nadeem, M. and Shamsi, T. (2013) Development of Factor VIII Inhibitors and Its Association with HLA Class I and II Alleles in Pakistani Hemophilia A Patients. Journal of Thrombosis and Haemostasis, 11, 926.
|
[26]
|
Liang, H., Yang, L.-H and Liu, X.-E. (2013) Correlation between Presence of Factor VIII Inhibitor and HLA-DQA1 Gene Polymorphisms. Chinese Remedies & Clinics, 13, 833-836.
|
[27]
|
Aytac, S., Altan, I., Üzümcügil, A., Gumruk, F. and Cetin, M. (2016) Combined Administration of FVIII and Bypassing Agents in the Management of Difficult Hemophilia A Patients with Inhibitor. Haemophilia, 22, 105-106.
|
[28]
|
Hodeib, H., El Amrousy, D., Youssef, A., Elaskary, E. and Fouda, M. (2022) BAFF rs9514828 Gene Polymorphism and the Risk of the Development of Inhibitors in Children with Severe Haemophilia A. Haemophilia, 28, 472-479. https://doi.org/10.1111/hae.14555
|
[29]
|
Soori, S., Dadashizadeh, G., Dorgalaleh, A., et al. (2019) Relationship between Single-Nucleotide Polymorphisms of Tumor Necrosis Factor Alpha, Interleukin-10, Factor II and Factor V with Risk of Inhibitor Development in Patients with Severe Hemophilia A. Cardiovascular & Hematological Disorders-Drug Targets, 19, 228-232. https://doi.org/10.2174/1871529X19666190206152315
|
[30]
|
El Demerdash, D., Ayad, A., Mohamed, D., Mattar, M. and Sadek, H. (2018) Study the Polymorphism of Tumor Necrosis Factor Alpha (TNF-α) Gene and the Risk of Development of FVIII Inhibitors in Egyptian Hemophilia A Patients: A Single Center Experience. Research and Practice in Thrombosis and Haemostasis, 2, 356-357.
|
[31]
|
Lu, Y., Ding, Q., Dai, J., Wang, H. and Wang, X. (2012) Impact of Polymorphisms in Genes Involved in Autoimmune Disease on Inhibitor Development in Chinese Patients with Haemophilia A. Thrombosis and Haemostasis, 107, 30-36. https://doi.org/10.1160/TH11-06-0425
|
[32]
|
Bachelet, D., Albert, T., Mbogning, C., et al. (2019) Risk Stratification Integrating Genetic Data for Factor VIII Inhibitor Development in Patients with Severe Hemophilia A. PLOS ONE, 14, e0218258. https://doi.org/10.1371/journal.pone.0218258
|
[33]
|
Boulassel, M.-R., Al-Ghonimi, M., Al-Balushi, B., et al. (2018) Regulatory B Cells Are Functionally Impaired in Patients Having Hemophilia A with Inhibitors. Clinical and Applied Thrombosis/Hemostasis, 24, 618-624. https://doi.org/10.1177/1076029617702244
|
[34]
|
Sadek, H., Youssry, I., Ibrahim, N.S.E., Abou-Elalla, A.A., Atef, G. and Mousa, S.M. (2017) The Development of FVIII Inhibitors in Relation to IL10 Gene Polymorphism in Hemophilia A Egyptian Pediatric Patients. Fetal and Pediatric Pathology, 36, 184-189. https://doi.org/10.1080/15513815.2017.1281363
|
[35]
|
Naderi, N., Ebrahimzadeh, F., Jazebi, M., Namvar, A., Hashemi, M. and Bolhassani, A. (2018) Polymorphisms in the TGF-β1 (rs1982037) and IL-2 (rs2069762, rs4833248) Genes Are Not Associated with Inhibitor Development in Iranian Patients with Hemophilia A. Hematology, 23, 839-843. https://doi.org/10.1080/10245332.2018.1498168
|
[36]
|
Marwanta, S., Muhammad, F., Maryono, S., et al. (2022) Association between Interleukin-2 (rs2069762) Gene Polymorphism and FVIII Inhibitor Development in Indonesian Patients with Severe Hemophilia A. Medical Journal of Indonesia, 31, 213-217. https://doi.org/10.13181/mji.oa.236439
|
[37]
|
Hassab, H., Hanafi, M., Abdelmaksoud, A. and ElSayed, S. (2018) Impact of Interleukin-6 and Interleukin-10 Gene Polymorphisms on Inhibitor Development in Patients with Moderate and Severe Hemophilia A. Blood, 132, 5026. https://doi.org/10.1182/blood-2018-99-117479
|
[38]
|
Ding, K.Y., Ji, W.C., Wu, J.S., Li, T. and Sheng, Y.Y. (2014) Higher Frequency of CD4 CD25High Treg Cells in Hemophilia Patients with Factor VIII Inhibitor. Genetics and Molecular Research, 13, 1774-1781. https://doi.org/10.4238/2014.March.17.5
|
[39]
|
El-Asrar, M.A., Hamed, A.E.S., Darwish, Y.W., Ismail, E.A.R. and Ismail, N.A. (2016) Assessment of the Frequency of Regulatory T Cells (CD4 CD25 CD127−) in Children with Hemophilia A: Relation to Factor VIII Inhibitors and Disease Severity. Blood Coagulation & Fibrinolysis, 27, 42-46. https://doi.org/10.1097/MBC.0000000000000377
|
[40]
|
Li, Y., Chen, Z., Li, G., et al. (2018) Expression of CTLA-4 and CD28 in Hemophilia A Children with FVIII Inhibitor. Journal of Capital Medical University, 3, 309-313.
|
[41]
|
Arandi, N., Zekavat, O.R., Shokrgozar, N., Shahsavani, A., Golmoghaddam, H. and Kalani, M. (2023) Altered Frequency of FOXP3 Regulatory T Cells Is Associated with Development of Inhibitors in Patients with Severe Hemophilia A. International Journal of Laboratory Hematology, 45, 953-960. https://doi.org/10.1111/ijlh.14139
|
[42]
|
Bafunno, V., Santacroce, R., Chetta, M., et al. (2012) Polymorphic miRNA-Mediated Gene Contribution to Inhibitor Development in Haemophilia A. Haemophilia, 18, 1003-1007. https://doi.org/10.1111/j.1365-2516.2012.02882.x
|
[43]
|
Astermark, J., Donfield, S.M., Gomperts, E.D., et al. (2013) The Polygenic Nature of Inhibitors in Hemophilia A: Results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood, 121, 1446-1454. https://doi.org/10.1182/blood-2012-06-434803
|
[44]
|
Chen, A.C., Cai, X., Li, C., Khoryati, L., Gavin, M.A. and Miao, C.H. (2020) A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated with Factor VIII Gene Therapy. Frontiers in Immunology, 11, Article 638. https://doi.org/10.3389/fimmu.2020.00638
|
[45]
|
Zuccherato, L.W., Elói-Santos, S.M., Jardim, L.L., et al. (2019) Variation of rs3754689 at Lactase Gene and Inhibitors in Admixed Brazilian Patients with Hemophilia A. Haematologica, 104, e527-e529. https://doi.org/10.3324/haematol.2019.220608
|
[46]
|
Mirbehbahani, N.B., Rashidbaghan, A., Livani, S. and Khosravi, A. (2015) Relation between Inhibitor Production and BclI/Intron 18 and VNTR ST14 Polymorphisms in an Iranian Population with Hemophilia A. Haematologica, 100, 672.
|
[47]
|
Mirbehbahani, N., Khosravi, A., Livani, S., Rashidbaghan, A., Jahazi, A. and Ebneghasem, R. (2020) The Role of Genetic and Environmental Factors in the Development of Inhibitors in Patients with Hemophilia A in the North of Iran. Egyptian Journal of Haematology, 45, 197-201. https://doi.org/10.4103/ejh.ejh_16_20
|
[48]
|
Fidancı, İ.D., Zülfikar, B., Kavaklı, K., et al. (2014) A Polymorphism in the IL-5 Gene Is Associated with Inhibitor Development in Severe Hemophilia A Patients. Turkish Journal of Haematology, 31, 17-24. https://doi.org/10.4274/Tjh.2012.0197
|
[49]
|
De Alencar, J.B., Macedo, L.C., De Barros, M.F., et al. (2015) New Associations: INFG and TGFB1 Genes and the Inhibitor Development in Severe Haemophilia A. Haemophilia, 21, e312-e316. https://doi.org/10.1111/hae.12685
|
[50]
|
Abdulqader, A.M.R., Mohammed, A.I. and Rachid, S. (2019) Polymorphisms in the Cytotoxic T Lymphocyte-Associated Protein-4 Immune Regulatory Gene and Their Impact on Inhibitor Development in Patients with Hemophilia A. Journal of International Medical Research, 47, 4981-4992. https://doi.org/10.1177/0300060519860329
|
[51]
|
Bahrami Zadegan, S., Mousavi, S.H., Damavandi, N., Samiee Aref, M.H. and Zeinali, S. (2020) Investigating the Influence of LCT rs3754689 Polymorphism on Inhibitor Development in Iranian and Afghan Patients with Severe Hemophilia A. Blood Coagulation & Fibrinolysis, 31, 11-15. https://doi.org/10.1097/MBC.0000000000000860
|
[52]
|
Liu, W., Lyu, C., Wang, W., et al. (2022) Risk Factors for Inhibitors in Hemophilia A Based on RNA-Seq and DNA Methylation. Research and Practice in Thrombosis and Haemostasis, 6, e12794. https://doi.org/10.1002/rth2.12794
|
[53]
|
Shang, B., Yang, S., Lei, P., et al. (2020) Clinical Study on Factor VIII Inhibitor in Children with Hemophilia A. Chinese Journal of Hematology, 41, 138-142.
|
[54]
|
Lochan, A., Macaulay, S., Chen, W., Mahlangu, J. and Krause, A. (2014) Genetic Factors Influencing Inhibitor Development in a Cohort of South African Haemophilia A Patients. Haemophilia, 20, 687-692. https://doi.org/10.1111/hae.12436
|
[55]
|
Gunasekera, D., Ettinger, R.A., Fletcher, S.N., et al. (2015) Factor VIII Gene Variants and Inhibitor Risk in African American Hemophilia A Patients. Blood, 126, 895-904. https://doi.org/10.1182/blood-2014-09-599365
|
[56]
|
Franchini, M., Coppola, A., Mengoli, C., et al. (2017) Blood Group O Protects against Inhibitor Development in Severe Hemophilia A Patients. Seminars in Thrombosis and Hemostasis, 43, 69-74. https://doi.org/10.1055/s-0036-1592166
|
[57]
|
Franchini, M., Coppola, A., Santoro, C., et al. (2021) ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers. Seminars in Thrombosis and Hemostasis, 47, 84-89. https://doi.org/10.1055/s-0040-1718870
|
[58]
|
Arshad, S., Singh, A., Awasthi, N.P., Kumari, S. and Husain, N. (2018) Clinicopathological Parameters Influencing Inhibitor Development in Patients with Hemophilia A Receiving On-Demand Therapy. Therapeutic Advances in Hematology, 9, 213-226. https://doi.org/10.1177/2040620718785363
|
[59]
|
Abdi, A., Eckhardt, C.L., Van Velzen, A.S., et al. (2021) Treatment-Related Risk Factors for Inhibitor Development in Non-Severe Hemophilia A after 50 Cumulative Exposure Days: A Case-Control Study. Journal of Thrombosis and Haemostasis, 19, 2171-2181. https://doi.org/10.1111/jth.15419
|
[60]
|
Marrugo, A.C., Noriega, N., Elles, R., Fontalvo, R., Florez, Tanus, A. and Alvis-Guzman, N. (2020) PRO40 Factors Associated with the Formation of Inhibitors in Patients with Hemophilia of the Subsidized Regime in Colombia. Value in Health, 23, S335-S336. https://doi.org/10.1016/j.jval.2020.04.1266
|
[61]
|
Susanah, S., Raspati, H., Sari, N.M., et al. (2021) Serum TNF-α Level as a Possible Predictor of Inhibitor Levels in Severe Hemophilia A. BioMed Research International, 2021, Article ID: 6483490. https://doi.org/10.1155/2021/6483490
|
[62]
|
Blatný, J., Kardos, M., Miljic, P., et al. (2021) Incidence of Inhibitor Development in PUPs with Severe Haemophilia A in the CEE Region between 2005 and 2015. Thrombosis Research, 198, 196-203. https://doi.org/10.1016/j.thromres.2020.12.004
|
[63]
|
Zhang, Q., Yang, X. and Liu, X. (2019) Study on Risk Factors and Follow-Up of Coagulation Factor VIII Inhibitor in Children with Hemophilia A. Chinese Journal of Thrombosis and Hemostasis, 25, 4-7.
|
[64]
|
Yada, K. (2021) Risk Factors of Inhibitor Development among Hemophilia Patients Revealed in a 10-Year Prospective Cohort Study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2). Rinsho Ketsueki, 62, 790-800.
|
[65]
|
Nyanchama, L., Magutu, V., Shikuku, K. and Ongondi, M. (2023) The Prevalence of and Risk Factors Associated with Factor VIII Inhibitors in Patients with Hemophilia A Seen at the Kenyatta National Hospital. International Journal of Laboratory Hematology, 45, 131-131.
|
[66]
|
van Velzen, A.S., Eckhardt, C.L., Peters, M., et al. (2013) Clinical Risk Factors in the Development of Inhibitors in Non-Severe Hemophilia A Patients: The First Results of the INSIGHT Case-Control Study. Journal of Thrombosis and Haemostasis, 11, 91.
|
[67]
|
Astermark, J., Ay, C., Carvalho, M., et al. (2022) New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia. Thrombosis and Haemostasis, 122, 905-912. https://doi.org/10.1055/a-1642-4067
|
[68]
|
Bolina-Santos, E., Chaves, D.G., Da Silva-Malta, M.C.F., et al. (2022) HCV Infection in Hemophilia A Patients Is Associated with Altered Cytokines and Chemokines Profile and Might Modulate the Levels of FVIII Inhibitor. Journal of Medical Virology, 94, 683-691. https://doi.org/10.1002/jmv.27432
|
[69]
|
Santos, E.M., de Melo Silva, J., Barbosa, A.N. and Pontes, G.S. (2022) Clinico-Epidemiological and Sociodemographic Profile of Patients with Hemophilia in the Brazilian Amazon: High Prevalence of Hepatitis C Infection and Its Possible Corrrelation with Inhibitor Development. Frontiers in Public Health, 10, Article 963790. https://doi.org/10.3389/fpubh.2022.963790
|
[70]
|
Van Helden, P.M., Van Haren, S.D., Fijnvandraat, K., Van Den Berg, H.M. and Voorberg, J. (2010) Factor VIII-Specific B Cell Responses in Hemophilia A Patients with Inhibitors. Haemophilia, 16, 35-43. https://doi.org/10.1111/j.1365-2516.2010.02215.x
|